2.35
-0.05(-2.08%)
Currency In USD
| Previous Close | 2.4 |
| Open | 2.33 |
| Day High | 2.35 |
| Day Low | 2.27 |
| 52-Week High | 17.88 |
| 52-Week Low | 1.11 |
| Volume | 240,186 |
| Average Volume | 375,693 |
| Market Cap | 45.79M |
| PE | -1.05 |
| EPS | -2.24 |
| Moving Average 50 Days | 1.64 |
| Moving Average 200 Days | 5.02 |
| Change | -0.05 |
If you invested $1000 in Annovis Bio, Inc. (ANVS) since IPO date, it would be worth $245.05 as of June 01, 2025 at a share price of $2.35. Whereas If you bought $1000 worth of Annovis Bio, Inc. (ANVS) shares 3 years ago, it would be worth $247.11 as of June 01, 2025 at a share price of $2.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annovis Bio Appoints Hui Liu as Director of Biostatistics
GlobeNewswire Inc.
Apr 29, 2025 12:00 PM GMT
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
GlobeNewswire Inc.
Mar 27, 2025 8:30 PM GMT
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
GlobeNewswire Inc.
Mar 25, 2025 12:00 PM GMT
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinso